AI Benchmarking Underscores Challenges in Drug Potency Prediction

According to a recent LinkedIn post from Insilico Medicine, the company’s ongoing ScienceAIBench series has reached a benchmark focused on IC50 prediction, a core metric in drug potency assessment. The post outlines an evaluation of several large AI models on their ability to predict how tightly drug candidates bind to biological targets, using the BindingDB Cold Drug split from the Therapeutics Data Commons.

The LinkedIn post highlights that Opus 4.5 achieved the highest performance in both Spearman and Pearson correlation, at approximately 0.35, while GPT 5.2 showed relatively stable behavior with fewer extreme outliers. By contrast, Deepseek 3.2 posted the weakest results, and all tested models recorded negative R² values, underscoring the difficulty of generalizing to novel chemical scaffolds in this benchmark setting.

For investors, the post suggests that Insilico Medicine is positioning itself as a methodical evaluator of third‑party AI models for drug discovery tasks, rather than simply relying on headline performance claims. Demonstrating nuanced understanding of model generalization to unseen chemical space may enhance the company’s credibility in AI‑driven drug design and support its competitive positioning in partnering or platform‑licensing discussions.

The moderate but consistent predictive signal reported in the benchmark also implies that current frontier models remain imperfect tools for structure–activity prediction, leaving room for proprietary model development and workflow integration. If Insilico Medicine can translate benchmarking insights into differentiated internal models or more efficient lead optimization, the long‑term impact could be improved R&D productivity and a more attractive asset pipeline, though the post itself does not provide direct financial or pipeline data.